Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697292 · ClinicalTrials.gov registry record · Phase 3
IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy
A Phase 3 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
NCT02697292: Clinical Trial Phase 3 study, sponsored by Mayo Clinic.
NCT02697292 is a Phase 3 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02697292, a Phase 3 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether intravenous immunoglobulin (IVIG) treatment reduces significantly the number of epileptic seizures in cases of autoimmune epileptic seizures.
Interventions
- DRUG Placebos
- DRUG Normal Saline
- DRUG Intravenous Immunoglobulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-12-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02697292
The ClinicalTrials.gov registry entry for NCT02697292 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebos is the first listed.
NCT02697292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02697292 about?
NCT02697292 is a clinical study titled "IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy". The purpose of this study is to determine whether intravenous immunoglobulin (IVIG) treatment reduces significantly the number of epileptic seizures in cases of autoimmune epileptic seizures.
What is the current status of trial NCT02697292?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2016-02. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT02697292?
The interventions under investigation include: Placebos (DRUG), Normal Saline (DRUG), Intravenous Immunoglobulin (DRUG).
Who is sponsoring clinical trial NCT02697292?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.